Role of NKG2D and its ligands in cancer immunotherapy
Huifang Liu1, Sijia Wang1, Jing Xin1
1Key Laboratory of Biomedical Information Engineering of Ministry of Education, Institute of Biomedical Analytical Technology and Instrumentation, School of Life Science and Technology, Xi'an Jiaotong University Xi'an, Shaanxi, China.
Abstract:
The activating receptor natural killer group 2, member D (NKG2D) is involved in both innate and adaptive immunities, and functions as a "master switch" in determining the activation status of natural killer (NK) cells. NKG2D binds to a diverse family of ligand molecules, which are only expressed at low levels in normal cells but can be upregulated by a cellular stress response. The NKG2D-NKG2D ligand (NKG2DL) pathway has been considered to be promising target for immunotherapy because of the selective expression of "stress-induced ligands" on tumor cells and the strong NK cell activating potency of NKG2D. Diverse strategies that are aimed at targeting the NKG2D pathway for cancer therapy are based on a thorough understanding of this mechanism, as well as that of NKG2D-mediated cancer immunity. In this review, we summarize the major findings regarding the antitumor immune response mediated by the NKG2D receptor and its ligands, and discuss the potential clinical applications of targeting the NKG2D/NKG2DL pathway for immunotherapy in cancer patients.
Insights
The NKG2D receptor acts as a master switch for natural killer (NK) cells, targeting stress-induced ligands on tumor cells. This pathway is a promising target for novel cancer immunotherapies.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Medicine
Background:
- The activating receptor NKG2D (natural killer group 2, member D) is crucial for innate and adaptive immunity, regulating natural killer (NK) cell activation.
- NKG2D ligands (NKG2DLs) are upregulated on cells under stress, including tumor cells, making them distinct targets.
- The NKG2D-NKG2DL pathway is a key mediator of anti-tumor immunity.
Purpose of the Study:
- To review major findings on NKG2D-mediated anti-tumor immune responses.
- To discuss the clinical potential of targeting the NKG2D/NKG2DL pathway in cancer immunotherapy.
Main Methods:
- This review synthesizes existing research on the NKG2D pathway and its role in cancer immunity.
- Analysis of studies investigating NKG2D-ligand interactions and their impact on NK cell activation.
Main Results:
- The NKG2D-NKG2DL pathway selectively targets tumor cells via stress-induced ligands.
- NKG2D activation demonstrates potent NK cell-mediated anti-tumor effects.
- Understanding this pathway is vital for developing effective cancer therapies.
Conclusions:
- Targeting the NKG2D/NKG2DL pathway offers a promising strategy for cancer immunotherapy.
- Further research into this pathway could lead to improved clinical applications for cancer patients.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...